Decitabine and Vorinostat Conditioning Followed by CD3-/CD19- NK Cells Infusion for High Risk Myelodysplastic Syndromes

Myelodysplastic Syndrome Clinical Trial

Official title:

Decitabine and Vorinostat With CD3/CD19 Depleted Haploidentical Donor Natural Killer (NK) Cells for the Treatment of High Risk Myelodysplastic Syndromes (MDS)

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01593670
• Other study ID #: 2011LS124
• Secondary ID: MT2012-04
• Status: Completed
• Phase: Phase 2
• Start date: March 2013
• Est. completion date: October 23, 2018

Study information

• Verified date: May 2019
• Source: Masonic Cancer Center, University of Minnesota
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This is a Phase II therapeutic trial combining Decitabine days 1-5 with oral Vorinostat twice daily days 6-15 followed by a single infusion of CD3-/CD19- enriched donor natural killer (NK) cells on day 17 and a short course of Interleukin-2 (IL-2) to facilitate NK cell survival and expansion. Two courses of treatment will be given separated by 6-8 weeks. The intent is to administer all treatment in the outpatient setting.

Description:

A single donor apheresis will be collected on day 15 of cycle 1, enriched for NK cells with the large scale CliniMacs device (Miltenyi) and activated by overnight incubation with IL-2. After washing, the final NK cell product will be divided in two, with half given fresh on day 17 of course #1 and half stored frozen until day 17 of course #2.

Clinical response will be formally assessed 4-6 weeks after the start of 2nd course based on International Working Group (IWG) criteria; however, bone marrow evaluations will be completed to assess for any sign of significant disease progression between cycle 1 and 2.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 9
• Est. completion date: October 23, 2018
• Est. primary completion date: October 23, 2018
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:

• Diagnosis of high risk myelodysplastic (MDS) that meets one of the following disease classifications and is requiring treatment:

• International Prognostic Scoring System (IPSS) Category: INT-2 or High Risk

• WHO Classification: RAEB-1 or RAEB-2

• High risk cytogenetic abnormality as defined by presence of Monosomy 7, complex karytope, or monosomal karyotype

• WHO Based Prognostic Scoring System (WPSS): High or Very High Risk

• Patients may be untreated or have had a maximum of 2 cycles of hypomethylating agents (azacitidine or decitabine) without evidence of treatment failure as defined by progression to more advanced MDS Who classification or AML. Patients must not have received treatment for their MDS within 4 weeks of beginning the trial. Treatments allowed prior to that time include azacitidine or decitabine and hematopoietic growth factors. No prior AML-like induction therapy allowed.

• Age = 18 years of age

• Eastern Cooperative Oncology Group (ECOG) Performance Status 0-2

• Available related HLA-haploidentical NK cell donor by at least Class I serologic typing at the A&B locus

• Have acceptable organ function within 14 days of enrollment

• Ability to be off prednisone and other immunosuppressive drugs for at least 3 days prior to the natural killer (NK) cell infusion

• Women of child bearing potential must agree to use effective methods of contraception

• Voluntary written consent

Exclusion Criteria:

• Pregnant or lactating.

• Prior 7 + 3 (cytarabine given continuously for 7 days with an anthracycline drug, such as daunorubicin or idarubicin given for the 1st 3 days of treatment) or other AML-type induction chemotherapy

• New progressive pulmonary infiltrates on screening chest x-ray or chest computed tomography (CT) scan that has not been evaluated with bronchoscopy (when feasible)

• Uncontrolled bacterial or viral infections - chronic asymptomatic viral hepatitis is allowed

• Pleural effusion moderate to large in size that are detectable on chest xray

• Known hypersensitivity to one or more of the study agents

• Prior hypomethylating treatment greater than 2 cycles or with documented treatment failure

• Prior use of histone deacetylase inhibitors

• Serious medical or psychiatric illness likely to interfere with participation in this clinical study in the opinion of the enrolling investigator

• Inability to swallow capsules

• Active human immunodeficiency virus (HIV)

• Other active and potentially life threatening malignancy excluding localized basal or squamous cell skin cancer, cervical carcinoma in situ, superficial bladder cancer, localized prostate cancer

Related Conditions & MeSH terms

• Myelodysplastic Syndrome
• Myelodysplastic Syndromes
• Preleukemia
• Syndrome

Intervention

Drug:
• Decitabine
administered intravenous (IV), 10 mg/m^2/day over 1 hour on days 1-5.
• Vorinostat
200 mg by mouth (PO) twice a day on days 6-15

Biological:
• Interleukin-2
6 million Units subcutaneous (SQ) 3 times a week for 3 doses beginning day 17

Other:
• Natural killer (NK) cells
infusion intravenously (IV) over 15 to 60 minutes day 17

Locations

Country	Name	City	State
United States	Masonic Cancer Center, University of Minnesota	Minneapolis	Minnesota
United States	Mayo Clinic	Rochester	Minnesota

Sponsors (2)

Lead Sponsor	Collaborator
Masonic Cancer Center, University of Minnesota	Mayo Clinic

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	The Number of Patients Who Achieved a Clinical Response	Clinical response includes: Complete Response (less than 5% myeloblasts present in the bone marrow and in the peripheral blood a hemoglobin of at least 11g/dl, platelets of at least 100 X 10E9/L, neutrophils of at least 1.0 X 10E9/L, and blasts 0%); Partial Response (all Complete Response criteria if previously abnormal except bone marrow myeloblasts are decreased by more than 50% over pre-treatment, but still greater than 5%); and hematologic improvement (a hemoglobin increase of greater than 1.5g/dl or decreased red blood cell transfusions by at least 4 per 8 week period, a platelet increase of more than 30 X 10E9/L for patients with a baseline of more than 20 X 10E9/L or an increase by 100% for those with a baseline of less than 20 X 10E9/L, and a neutrophil increase of at least 100% and an absolute increase of greater than 0.5 X 10E9/L.	After 2 Courses of Treatment (Approx. 3 months)
Secondary	Number of Patients Who Experienced Grade 3 or Higher Non-hematologic Adverse Events	Adverse events (AEs) will be graded using Common Terminology Criteria for Adverse Events v4.0 (CTCAE). Non-hematologic adverse events are defined as untoward medical occurrences associated with the use of a study drug whether or not considered study drug related, excluding those events involving white blood cells, neutrophils, red blood cells or platelets. In general, grade 3 AEs are defined as 1) being severe or medically significant but,not immediately life-threatening; 2) requiring hospitalization or prolongation of hospitalization; 3) disabling; or 4) limiting self care activities. Grade 4 AEs are defined as 1) having life-threatening consequences; or 2) requiring urgent intervention. Grade 5 AEs are defined as causing death related to an adverse event.	Day 1 through Month 3
Secondary	Number of Patients Who Became Transfusion Independent		4-6 Months Post Start of Cycle 1
Secondary	Number of Patients Who Had Natural Killer (NK) Cell Expansion	NK cell expansion is defined as the presence of donor NK cells in the recipient at Day 8 post NK cell infusion.	After Cycle 2 (approx. 3 months)
Secondary	Overall Survival	Patients alive at 1 year.	1 Year